Ask AI
ProCE Banner Series

Conversations in Melanoma: Perspectives on Immunotherapy in Resectable and Unresectable Disease

Join us for this online, interactive roundtable webinar as expert faculty on melanoma describe the role of immunotherapy in the current treatment landscape from neoadjuvant therapy through treatment for metastatic disease and discuss current dilemmas in therapy selection. Register now!

To Register: Please click the green “Learn More” button below. On the next page, select Register for Virtual Event. Once registered, you will receive a confirmation email. Follow-up emails with event details will be sent as the event nears.

Not an official event of the 2023 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation

  AMA
Credits Available

1.0

Who Should Attend

This program is intended for oncologists and other multidisciplinary care team members involved in the care of patients with melanoma.

All Events

Conversations in Melanoma: Perspectives on Immunotherapy in Resectable and Unresectable Disease

Past Events

June

02

2023

10:30 AM - 11:30 AM Central Time (CT)

Virtual

Topics

Conversations in Melanoma: Perspectives on Immunotherapy in Resectable and Unresectable Disease

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

CME/CE Info

Goal Statement
This program aims to improve learners’ knowledge, confidence, and competence in integrating the latest clinical guidance and expert recommendations for immunotherapy (collectively PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) and targeted therapies (BRAF/MEK inhibitors) in early-stage and advanced-stage melanoma. 

Target Audience
This program is intended for oncologists and other multidisciplinary care team members involved in the care of patients with melanoma. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Consider evidence-based research findings and guideline recommendations for the use of immunotherapy (PD-1–, CTLA-4–, and LAG-3–directed immunotherapy) along with targeted therapies in melanoma, including adjuvant therapy, neoadjuvant therapy, or combined immunotherapy and targeted therapy for unresectable, metastatic disease
  • Devise treatment plans that incorporate immunotherapy for appropriate patients with resectable and unresectable melanoma, including those with BRAF-mutant or BRAF wild-type disease
  • Manage immune-related adverse events related to the use of immunotherapy in patients with melanoma across the spectrum of disease

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Bristol Myers Squibb.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191